Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction

Lipids in Health and Disease

Olga Barbarash¹  Alexander Shilov¹  Victoria Karetnikova¹  Ekaterina Belik¹  Yulia Dyleva¹  Evgenya Uchasova¹  Olga Gruzdeva¹ 

[1] Research Institute for Complex Issues of Cardiovascular Diseases under the Siberian Branch of the Russian Academy of Medical Sciences, Kemerovo, Russia

关键词: Antibodies;    Oxidized LDL;    Free fatty acid;    Myocardial infarction;   

Others  :  1159983
DOI  :  10.1186/1476-511X-13-111

 received in 2014-04-29, accepted in 2014-07-01,  发布年份 2014

【 摘 要 】

Background

Free fatty acids (FFA), oxidized low-density lipoprotein (LDL) and its antibodies, lipid profile markers, which are formed under oxidative stress, play an important role in atherosclerotic disease. Assess the levels of these markers in myocardial infarction patients depending on the extent of coronary artery disease (CAD).

Methods

ST-elevation MI patients with hemodynamically significant stenoses of ≥75% in one, two, three, or more coronary arteries were examined. The patients were divided into three groups according to the severity of coronary lesions. Patients had a ≥75% stenotic lesion in one coronary artery (group 1, n = 135), two coronary arteries (group 2, n = 115), or three or more coronary arteries (group 3, n = 150). The control group comprised healthy subjects (n = 33).

Results

FFA levels on day 1 from MI onset were higher in groups 1, 2, and 3 compared with controls. On day 1 from MI onset, oxidized LDL levels were significantly higher in groups 2 and 3 than those in controls (both р = 0.001). Oxidized LDL levels were significantly higher in patients with multivessel CAD compared with those with single-vessel CAD on days 1 and 12. Antibody levels increased with the number of affected arteries.

Conclusion

High levels FFA, oxidized LDL and its antibody, lipid profile markers, and parameters of the pro/antioxidant systems persist during the subacute phase of MI.

【 授权许可】

   
2014 Gruzdeva et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW: Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007, 28(14):1709-1716.
• [2]Parodi G, Memisha G, Valenti R, Trapani M, Migliorini A, Santoro GM, Antoniucci D: Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience. Heart 2005, 91(12):1541-1544.
• [3]Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Author information. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108(22):2751-2756.
• [4]Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:Results of AF CAPS/TexCAPS.AirForce/TexasCoronaryAtherosclerosisPreventionStudy. JAMA 1998, 279(20):1615-1622.
• [5]Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA 1986, 256(20):2835-2838.
• [6]Taegtmeyer H, McNulty P, Young ME: Adaptation and Maladaptation of the Heart in Diabetes: Part I General Concepts. Circulation 2002, 105(33):1727-1733.
• [7]Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A: Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardio 1996, 78(12):1350-1354.
• [8]Pirro M, Mauriège P, Tchernof A, Cantin B, Dagenais GR, Després JP, Lamarche B: Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Atherosclerosis 2002, 160(2):377-384.
• [9]Opie LH, Knuuti J: The adrenergic-fatty acid load in heart failure. J Am CollCardiol 2009, 54(18):1637-1646.
• [10]Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
• [11]Naruko T, Ueda M, Ehara S, Itoh A, Haze K, Shirai N, Ikura Y, Ohsawa M, Itabe H, Kobayashi Y, Yamagishi H, Yoshiyama M, Yoshikawa J, Becker AE: Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol 2006, 26(4):877-883.
• [12]Van der Vusse GJ, Van Bilsen M, Glatz JF, Hasselbaink DM, Luiken JJ: Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem 2002, 239(1–2):9-15.
• [13]Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC: Myocardial Fatty Acid Metabolism in Health and Disease. Physiol Rev 2010, 90(1):207-258.
• [14]Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1(7285):785-789.
• [15]Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, De Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the Thirty-Person/Ten-Country Panel. J Intern Med 2006, 259(3):247-258.
• [16]Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipopro-tein Al, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358(9298):2026-2033.
• [17]Virella G, Lopes-Virella M: Lipoprotein Autoantibodies:Measurement and Significance. Clin Diagn Lab Immunol 2003, 10(4):499-505.
• [18]Steinberg D: Low density lipoprotein oxidation and its pathological significance. J BiolChem 1997, 272(34):20963-20966.
• [19]Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Ylä-Herttuala S: Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Bio 2000, 20(1):204-209.